ACLX beat EPS expectations by 8.44%
Nov 07, 2025, 11:37 PM
0.00%
What does ACLX do
Arcellx, based in Redwood City, California, focuses on innovative immunotherapies for cancer, with its lead product, CART-ddBCMA, in pivotal Phase II trials for multiple myeloma. The company also develops two clinical-stage programs targeting BCMA and CD123 in various blood cancers.
Arcellx (ACLX) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Arcellx's actual EPS was -$0.99, beating the estimate of -$1.08 per share, resulting in a 8.44% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.